| 1 |
28389270 | Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts. | 2017 Sep |
2 |
| 2 |
25042492 | [Effect of valproic acid on SMN protein level in peripheral blood mononuclear cells of patients with spinal muscular atrophy and different SMN2 copy numbers]. | 2014 |
1 |
| 3 |
25143843 | Valproate Treatment in an ALS Patient Carrying a c.194G>A Spastin Mutation and SMN2 Homozygous Deletion. | 2014 |
1 |
| 4 |
23077215 | VPA response in SMA is suppressed by the fatty acid translocase CD36. | 2013 Jan 15 |
4 |
| 5 |
21561730 | Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines. | 2012 Mar |
6 |
| 6 |
21610752 | Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability. | 2011 Oct |
1 |
| 7 |
18025935 | Clinical trials in spinal muscular atrophy. | 2007 Dec |
1 |
| 8 |
16508748 | Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. | 2006 May |
1 |
| 9 |
16775228 | Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. | 2006 Aug 8 |
1 |
| 10 |
17027862 | Spinal muscular atrophy: from gene to therapy. | 2006 Jun |
2 |
| 11 |
17076267 | Spinal muscular atrophy and therapeutic prospects. | 2006 |
2 |
| 12 |
12915451 | Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. | 2003 Oct 1 |
5 |